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Abstract 
Aims. We investigated the association between worsening renal function (WRF) that occurs 
during renin angiotensin aldosterone system inhibition initation and outcome in heart failure 
(HF) patients with preserved ejection fraction (HFPEF) and compared this with HF patients 
with reduced ejection fraction (HFREF). 
Methods and Results.We examined changes in estimated glomerular filtration rate (GFR) 
and the relationship between WRF (defined as e26.5 µmol/L and e25% increase in serum 
creatinine from baseline to 6 weeks) and outcome, according to randomized treatment, in 
patients with HFREF (EF <45%; n=1569) and HFPEF (EF e45%; n=836) in the CHARM 
program. The primary outcome was cardiovascular death or HF hospitalization. Estimated 
GFR decreased 9.0±21 versus 4.0±21 mL/min/1.73m2 with candesartan and placebo, 
respectively, and this was similar in HFREF and HFPEF. WRF developed more frequently 
with candesartan 16 vs. 7%, P<0.001, with similar findings in patients with HFREF and 
HFPEF. WRF was associated with a higher risk of the primary outcome: multivariable hazard 
ratio (HR) 1.26, 1.03-1.54, P=0.022, in both treatment groups, and in HFREF and HFPEF (P 
for interaction 0.98). In HFREF, WRF was mostly related to HF hospitalization, while in 
HFPEF, WRF seemed more associated with mortality.  
Conclusions. GFR decreased more and WRF was more common with candesartan compared 
with placebo, and this was similar in HFREF and HFPEF. WRF was associated with worse 
outcomes in HFREF and HFPEF. Although no formal interaction was present, the association 
between candesartan treatment, WRF and type of clinical outcome was slightly different 
between HFREF and HFPEF.  
 
Key Words. Worsening Renal Function, HFPEF, HFREF, Prognosis, Angiotensin Receptor 
Blocker
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Introduction 
Chronic kidney disease (CKD) and worsening renal function (WRF) are important prognostic 
factors both in patients with heart failure (HF) and reduced fraction and in those with 
preserved ejection fraction (HFREF and HFPEF, respectively).1,2 
However, evidence-based therapies that can worsen renal function, such as renin angiotensin 
aldosterone system (RAAS) inhibitors, improve outcome in HFREF, even in patients with 
pre-existing CKD.3-5 Importantly, new evidence suggests that worsening of renal function 
during the initiation of a RAAS inhibitor, may not have the same adverse prognostic 
implications as WRF in other circumstances.3-6 
For patients with HFPEF, data on WRF and outcome are scarce and data on the effect of 
treatment on the association between WRF and outcome are limited to one retrospective 
analysis of the I-Preserve trial with irbesartan.7  In that analysis, WRF during initiation of 
irbesartan treatment was associated with an increased risk of cardiovascular death or HF 
hospitalization. This finding contrasts strikingly with those reported previously in studies in 
HFREF. The Candesartan in Heart failure Assessment of Reduction in Mortality and 
morbidity trials (CHARM) offer another opportunity to investigate the relationship between 
WRF and outcome in patients with HFPEF, and the effect of treatment with an angiotensin 
receptor blocker (ARB) on that relationship. Moreover, the same analyses are possible in 
patients with HFREF who were also enrolled in CHARM, allowing a direct comparison 
between patients with these two types of chronic HF. 
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Methods 
In the CHARM program patients with symptomatic HF were randomly assigned to either 
candesartan or placebo.8,9 Patients with a left ventricular ejection fraction (LVEF) d 40% 
were randomized into CHARM-Alternative (N=2028) if they were intolerant of an 
angiotensin converting enzyme inhibitor (ACEi) or CHARM-Added (N=2548) if taking an 
ACEi. Patients with a LVEF > 40% were enrolled in CHARM-Preserved (N=3023). A key 
exclusion criterion was a serum creatinine e  265 µmol/L (3 mg/dL). The present analyses 
were carried out in the 2500 patients with a central laboratory measurement of creatinine at 
baseline and follow-up (6 weeks, 14 months and 26 months), all of whom were enrolled in 
North America (See supplementary Table 1 for the number of patients in each of the 
component trials in the CHARM Programme).10 
 For the present analyses, HFPEF was defined as LVEF e45% (with HFREF defined as 
LVEF <45%) to reflect more recent definitions of this syndrome and to be consistent with I-
Preserve. Only patients with a serum creatinine at baseline and at least at the 6 week post-
randomization visit were included. All patients gave written informed consent before being 
enrolled. All participating sites received approval from local ethics committees for the 
conduct of the study program. 
 
Glomerular Filtration Rate and Worsening Renal Function 
Estimated glomerular filtration rate (eGFR, mL/min/1.73m2) was calculated using the 
simplified Modification of Diet in Renal Disease formula and Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI). There is no universal definition on WRF, and 
international guidelines do not agree on the best method in establishing WRF.11-13 In this 
study, WRF was defined as both an absolute increase in serum creatinine of e  26.5 µmol/L 
(e0.3 mg/dL) and together with a relative increase in serum creatinine of e  25% between 
baseline and 6 weeks during the uptitration phase of the CHARM-studies in the chronic 
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outpatient setting. In addition, as sensitivity analyses, we also examined WRF defined as an 
absolute increase in serum creatinine of e  26.5 µmol/L ora reduction in eGFR of either e  
20% or e  30%.  
 
Clinical Outcomes 
The primary outcome of each of the CHARM trials was the first occurrence of cardiovascular 
death or HF hospitalization. Secondary outcomes included all-cause mortality, HF 
hospitalization, combined endpoint of all-cause mortality or HF hospitalization and a 
composite of major adverse cardiac events (cardiovascular death, admission to hospital for 
HF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation). 
 
Statistical Analysis 
Data are reported as mean ± standard deviation when normally distributed, as median and 
interquartile ranges when the distribution was skewed and as frequencies and percentages for 
categorical variables. Student’s t test or Mann-Whitney U tests were used to determine 
significant differences of variables between patients with and without WRF in both treatment 
groups, and in patients with HFREF and HFPEF. All patients that received the study 
treatment were included in this analysis and analysed according their treatment group. 
Logistic regression was used to determine odds ratios (OR) for the occurrence of WRF at 6 
weeks for candesartan treatment compared with placebo. Change in renal function over time 
was assessed by repeated analysis mixed effect modelling using unstructured covariance. The 
variables already reported to be of prognostic value in this CHARM were used in 
multivariable modelling (age, gender, race, NYHA functional class, smoking status, LVEF, 
systolic and diastolic blood pressure, heart rate, history of angina, stroke, hypertension, 
diabetes, myocardial infarction and HF hospitalization, as well as certain medical therapies: 
diuretic, ACE-inhibitor, spironolactone, calcium channel blocker, other vasodilators and 
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aspirin)10 We included a random intercept accounting for possible differences on patient 
level. To evaluate possible association between candesartan use or early discontinuation, 
change in blood pressure and WRF we used exploratory analysis evaluating the change in 
mean arterial pressure and disconuation rates among patients with and without WRF. We 
used a Cox proportional hazards model to estimate hazard ratios (HR) with 95% CI for the 
occurrence of the primary and all secondary endpoints. WRF was added to the model as a 
categorical variable. Interaction terms with treatment (WRF x treatment) were analysed 
separately. The Cox proportional hazard assumption was checked by visual inspection of the 
log-log plots and statistical testing of Schoenfeld residuals no violations were observed. 
Kaplan-Meier survival curves were plotted showing outcomes in patients who did or did not 
experience WRF in both treatment groups and in patients with HFREF and HFPEF. A 2-
tailed P-value < 0.05 was considered significant, except for interactions where P-value < 0.10 
was considered significant. Statistical analyses were performed using STATA, College 
Station, Texas, version 12.0.
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Results 
A total of 2405 out of 2500 (96%) patients had both a baseline and 6 week creatinine 
available. Of these 589 (24%), 836 (35%) and 980 (41%) were from the CHARM-
Alternative, -Added and –Preserved trials, respectively. Differences between patients from 
North-America and elsewhere in CHARM have been described previously.9 
 
 
Baseline characteristics and Worsening Renal Function 
Baseline characteristics, stratified by treatment allocation and development of WRF are 
presented in Table 1 and stratified for HFREF and HFPEF in Table 2. There were few 
differences in baseline characteristics for patients with and without WRF. Examining WRF 
according to treatment assignment, patients developing WRF in the candesartan group more 
often received diuretics and beta-blockers, and had lower average hemoglobin levels than 
those who did not develop WRF. 
In the overall CHARM population, WRF developed in 282 (12%) of patients at week 6, and 
was more common with candesartan than with placebo: odds ratio (OR) 2.44 (1.88-3.19), P < 
0.001 (Table 3). Similar findings were observed using different definitions of WRF, and 
across the component trials of the CHARM Program (Supplementary Table 1).  
WRF occurred in 12% of patients with HFREF. The most notable differences between 
patients with and without WRF in HFREF were more frequent use of loop diuretics and 
ACE-inhibitors in the WRF group. Similarly to HFREF, WRF occurred in 12% of patients 
with HFPEF. Among differences, patients who experienced WRF in HFPEF more frequently 
had a history of coronary artery disease or ischemic HF.  
 
WRF and Clinical Outcome 
CHARM-Overall 
8 
 
Table 4 shows the association between WRF and clinical outcome. WRF was related to the 
primary outcome of CV death or HF hospitalization in the entire CHARM population and this 
association remained after multivariable adjustment, although it was attenuated to some 
extent (HR 1.26, 1.03-1.54, P = 0.022) (Table 4). WRF was most consistently associated with 
HF hospitalisation, rather than CV death or all-cause mortality. The relationship between 
WRF and outcome was not influenced by study-drug discontinuation in the entire population 
and HFREF or HFPEF patients. Also, baseline eGFR did not modify the association between 
WRF, candesartan treatment and associated outcome (P for interaction 0.35). Supplementary 
table 2 shows the association between WRF, treatment and outcome in different CHARM 
studies. We found no evidence of a significant interaction between study arm allocation and 
the association between candesartan treatment, WRF and outcome. Additionally, there was 
no interaction between candesartan treatment, WRF, baseline LVEF (as a continuous 
measure) and relationship with outcome (P=0.771). Supplementary table 3 shows the 
association between the effect of candesartan treatment on outcome, and baseline WRF in 
different phenotypes of HF, showing no evidence of interaction and similar effects of 
candesarta in patients with and without WRF. 
 
CHARM HFREF 
In patients with HFREF, there was a clear association between the occurrence of WRF and 
the primary outcome of CV death or HF hospitalization in univariate analysis (HR 1.46, 1.17-
1.83, P = 0.001), which persisted after adjustment for other prognostic variables and 
concomitant therapy (Figure 1A and Table 4). WRF was an independent predictor of this 
composite outcome in both the placebo and candesartan group, without evidence of 
interaction. After adjustment for other prognostic variables and concomitant therapy, there 
was a persisting association between WRF and HF hospitalization in both treatment groups, 
but not for other outcomes.  
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CHARM HFPEF 
Development of WRF showed the same trend with occurrence of the primary outcome  
(adjusted HR 1.30, 0.89–1.90), compared with patients with HFREF (P for interaction 0.98). 
However, this association did not reach statistical significance in either treatment group, after 
adjustment for the prespecified prognostic variables and concomitant therapy (Figure 1B, 
Table 4). Similar results were found secondary outcomes, with the exception of CV death. 
For this particular outcome, there was trend towards an interaction (P=0.10) between WRF 
and treatment; WRF was associated with a higher risk of CV death in patients allocated to 
candesartan in contrast to WRF that occurred with placebo. There was no significant 
interaction between treatment, WRF and outcomes on multivariable analysis.  
 
Change in eGFR 
For all patients, the mean baseline eGFR at baseline was 71 ± 27 mL/min/1.73m2. Overall, 
estimated GFR decreased by 2.8 mL/min/1.73m2/year, to 66 ± 27 mL/min/1.73m2 at 26 
months in surviving patients. Candesartan treatment was associated with a significantly 
greater decrease in eGFR at 6 weeks than placebo: -4.7 ± 19 versus -0.1 ± 19 mL/min/1.73m2 
(P< 0.001), respectively (Figure 2A). The difference between candesartan and placebo in 
change in was similar in patients with or without a history of diabetes at baseline (in both HF 
phenotypes). 
Similar results were found for HFREF and HFPEF. Figures 2B and C show the time courses 
of eGFR in patients with HFREF and HFPEF, respectively. In patients with HFREF, mean 
eGFR decreased by -6.4 ± 21 mL/min/1.73m2 overall. The change in eGFR was more 
pronounced in the candesartan group -8.9 ± 22 versus -3.9 ± 21 mL/min/1.73m2 for placebo 
at 26 months follow up (P < 0.001).). In patients with HFPEF, eGFR decreased by -6.7 ± 21 
mL/min/1.73m2 at 26 months, a decline similar to that observed in the HFREF group (P = 
0.91). Patients in the candesartan group showed a greater decrease in eGFR at 26 months: -
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9.2 ± 21 mL/min/1.73m2 versus -3.8 ± 20 mL/min/1.73m2 in the placebo group (P = 0.042). 
In both HFREF and HFPEF, using the CKD-EPI instead of sMDRD formula showed similar 
results. Supplementary table 4 summarizes the change in eGFR across HF phenotypes, 
randomized candesartan treatment and study periods. 
 
Change in mean arterial pressure and discontinuation rates 
The reduction in mean arterial pressure (MAP) at 6 weeks was greater in patients with WRF 
than in those without (-7.9 ± 12 vs. -2.8 ± 11 mmHg , P < 0.001) and patients in the 
candesartan group with WRF had greater reductions in MAP than patients with WRF in the 
placebo group (-9.5 ± 11 vs. -4.4 ± 14 mmHg, P = 0.001). These results were similar in 
HFREF and HFPEF, although the difference of change in MAP between patients with WRF 
on either placebo or candesartan in HFPEF was numerically, but not statistically, different.  
Permanent discontinuation rates within 6 weeks after the second creatinine measurement 
were significantly higher in patients with WRF, compared to those without WRF (7 vs 2%, P 
< 0.001). Similar discontinuation rates were observed before WRF occurred (1 vs 2%, P = 
0.36). The findings were similar in HFREF and HFPEF. 
 
Discussion 
In the present study, eGFR decreased more with candesartan compared with placebo, and this 
was similar in HFREF and HFPEF. We found that the incidence of WRF was similar in 
patients with HFREF and HFPEF, overall and separately within the placebo group and 
candesartan group. Candesartan was associated with a higher incidence of WRF in both types 
of HF. Overall WRF was associated with worse clinical outcomes. There was no significant 
interaction between type of HF (or LVEF on a continuous scale), candesartan treatment, 
occurrence of WRF and the relationship with outcome.  
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Change in eGFR and ARB treatment 
CKD as defined by a reduced eGFR is frequently present in chronic HFREF and HFPEF 
patients.1 While there are plentiful data on baseline CKD in HF (mostly HFREF), there are 
fewer data on change in eGFR over time. In HF patients that were followed after 
hospitalization, eGFR decreased 7.0 mL/min/1.73m2 in the next 18 months.14 
 In Val-HeFT, patients in the placebo group had a mean decrease of 2.9 mL/min/1.73m2 after 
36 months.4 In I-Preserve, the mean change in eGFR over 30 months was 5.0 
mL/min/1.73m2, which was more pronounced in the irbesartan group.7 Our results are in 
alignment with these findings. We found a decrease in 4.0 mL/min/1.73m2 over 26 months. 
In keeping with the results of Val-HeFT and I-Preserve, candesartan treatment led to an early  
(although small) decline in eGFR.4,7 This initial decline in GFR is thought to be due to 
inhibition of the effect of angiotensin on glomerular efferent arterial tone leading to 
decreased filtration pressure and decreased GFR. This effect was similar in patients with 
HFREF and HFPEF.  After the initial steep fall in eGFR, there was a subsequent slower 
decrease in eGFR and this was similar in the placebo and candesartan group. Thus, it seems 
clear from Val-HeFT, I-Preserve and CHARM that ARBs do not preserve renal function in 
patients with HFREF or HFPEF in contradistinction to patients with diabetic nephropathy.15,16 
 
 
Worsening Renal Function, Outcome and candesartan treatment in HFREF 
WRF, however defined, is associated with poor clinical outcomes in chronic HF although the 
data supporting this conclusion come predominantly from studies in patients with HFREF.2 
 In SOLVD the incidence of WRF with enalapril was similar to what we found in CHARM. 
WRF on enalapril was not associated with worse clinical outcome, in contrast to the placebo 
group.3 Similarly, in Val-HeFT, valsartan treatment was associated with an increased 
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frequency of WRF compared with placebo (12.3 vs. 5%, respectively), but the beneficial 
effect of valsartan over placebo was maintained, even in patients experiencing WRF.4 
 Some increase in serum creatinine is frequently observed after initiation of an ACE inhibitor, 
and the European Society of Cardiology HF guidelines suggest only reducing the dose of 
ACE/ARB therapy (or stopping treatment) when such increases are large i.e. >50% or when 
the absolute creatinine concentration exceeds 266 µmol/L (3 mg/dL), while the 2013 
ACC/AHA HF guidelines mainly suggest monitoring renal function closely. This relatively 
relaxed approach reflects the belief that an initial decrease in renal function as a result of 
RAAS inhibition is not thought to be detrimental with respect to clinical outcome unless 
extreme. This is supported by a meta-analysis of RAAS inhibitor trials examining the 
relationship between WRF and outcome which showed that the beneficial effects of these 
drugs over placebo were maintained, even in the presence of WRF.6 
 In CHARM, WRF in patients with HFREF was independently associated with a higher risk 
of the composite endpoint of CV death or HF hospitalization, and this was primarily 
attributable to an association with HF Hospitaliations. In SOLVD the increased risk related to 
WRF (versus no WRF) was greater in the placebo than in the enalapril group for the endpoint 
of all-cause mortality and HF hospitalization was not assessed.3 
 In RALES, EMPHASIS-HF and EPHESUS, WRF seemed to be more strongly associated 
with HF hospitalization than with all-cause mortality.51718 
 A similar association was seen in HF-REF patients in CHARM, although in the candesartan 
group the risk of HF hospitalization related to WRF was not increased as much in the 
candesartan group as in the placebo group. It has been difficult to predict beforehand which 
patients will experience WRF (and have poor outcome).2 Also from our present analysis, no 
specific factors, other than severity of heart failure were significantly associated with the 
occurrence of WRF, irrespective of outcome and treatment.   
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Worsening Renal Function, Outcome and candesartan treatment in HFPEF 
Only two studies to date have examined the prognostic importance of WRF in patients with 
HFPEF, and in the largest, an analysis from I-Preserve, the picture was different than in 
HFREF.7,19 In I-Preserve, the risk of WRF was twice as high in patients allocated to irbesartan 
( 8 vs. 4%) consistent with what is seen with an ACEi or ARB in HFREF. WRF in the entire 
study population, irrespective of study drug allocation, was associated with a greater risk of 
cardiovascular death or HF hospitalization. In contrast to HFREF, WRF in I-Preserve patients 
allocated to irbesartan was associated with poor clinical outcome, which was even worse 
compared with WRF that occurred in patients allocated to placebo. In patients with HFPEF in 
CHARM, WRF also appeared to be associated with worse outcomes although this finding 
was not statistically significant, possibly due to the relatively small number of patients an 
events studied. WRF occurring during candesartan treatment in HFPEF patients was 
associated with a higher risk of CV death, while this relationship was less clear in patients 
receiving placebo or for other endpoint such as HF hospitalization, which was the 
predominant association with WRF for HFREF patients. Although this apparent difference 
could reflect the play of chance, it might also indicate that the consequences of ARB-related 
WRF are different in patients with HFPEF compared with HFREF. We believe that this 
hypothesis is possible as WRF in the irbesartan group in I-Preserve was also mainly 
associated with a higher risk of all-cause death, in contrast to that in the placebo group 
(multivariable P-value for interaction 0.078).7  However, in our current analysis when LVEF 
was examined as a continuous variable, there was no interaction between WRF, treatment 
and outcome. Therefore, we cannot be sure that patients with HRPEF definitely do differ 
from those with HFREF, although patients with HFPEF and HFREF are dissimilar not only 
in relation to ejection fraction, but also in relation to demographics, the pathophysiology of 
heart failure,and therefore possible also in the relationship between WRF and outcome. 
Finally, we know that ACE inhibitors and ARBs do not improve outcomes in HFPEF in 
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contrast to HFREF.20,21 Therefore, whereas any detrimental effect of RAAS inhibition may be 
entirely outweighed by benefit in HFREF, this will not be the case in HFPEF. 
 
Clinical Perspective on difference between WRF in HFREF and HFPEF 
In HFREF, if WRF develops during RAAS-inhibition, treatment should be continued as 
RAAS inhibition remains advantageous overall, although the benefit may be attenuated 
(compared with patients not developing WRF), especially with respect to HF hospitalization.  
The picture is different in HFPEF patients. Despite the fact that RAAS-inhibitors have not 
been shown to reduce mortality or morbidity in these individuals, RAAS blockers are 
frequently used, presumably, in the majority of cases, to treat hypertension. RAAS blockade 
leads to a drop in eGFR and induces WRF at a similar rate to that observed in HFREF. The 
findings of the present analysis from CHARM, together with those from I-PRESERVE, 
suggest that clinicians should monitor for development of WRF when a RAAS blocker is 
used in these patients because its occurrence is associated with worse clinical outcomes than 
in patients without WRF. If WRF does develop, an alternative treatment, if available, should 
be considered. 
 
Limitations 
This was a retrospective analysis of a randomized controlled trial, and therefore these results 
can only be extrapolated to the general HF population with caution. Not all patients had 
serum creatinines available, and as such selection bias could have arisen. However, serum 
creatinine determination was done by protocol, which minimizes the bias of having more 
creatinine values available for high risk patients. The definition of WRF used in this analysis 
accounts for the exponential relationship between serum creatinine and eGFR, but there is no 
universal definition of WRF and other definitions might have given different results. On the 
other hand, our sensitivity analyses with different estimates of WRF showed similar results. 
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We had no data on dose of diuretics, which could have been helpful in determining the 
association between diuretic use, WRF and clinical outcome. We cannot account for 
unmeasured confounding from known (such as natriuretic peptides) and unknown variables. 
 
Conclusions 
Initiation of candesartan led to an immediate but small reduction in eGFR which was similar 
in patients with HFREF and HFPEF. Approximately one in eight patients reached the 
threshold for WRF which also occurred with equal frequency in HFREF and HFPEF. WRF 
was associated with worse clinical outcomes, particularly HF hospitalization in HFREF, and 
mortality in HFPEF. This association was observed in both the placebo and candesartan 
groups although the magnitude of excess risk related to WRF was less in the candesartan 
group. Overall,  observations were similar in patients with both HFREF and HFPEF, although 
subtle differences for different endpoints in multivariable analysis were observed, suggesting 
that at least some caution should be exercised in HFPEF patients who develop WRF on ARB 
therapy.  
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Figure Legends 
Figure 1. Candesartan treatment, Worsening Renal Function and CV death or HF 
Hospitalization 
A) Patients with HFREF 
B) Patients with HFPEF 
Abbreviations: CV: Cardiovascular, HF: Heart Failure, WRF: Worsening Renal Function 
 
Figure 2: Change in eGFR stratified for treatment 
A) Entire CHARM population 
B) Patients with HFREF 
C) Patients with HFPEF 
$ P < 0.050, # P < 0.01, * P < 0.001. P for overall interaction < 0.001. Abbreviations: eGFR: 
estimated Glomerular Filtration Rate. Presented are least square means ± standard error from 
adjusted mixed effects model. Random intercept on patient level, fixed effects: age, gender, 
race, NYHA functional class, smoking status, left ventricular ejection fraction, systolic and 
diastolic blood pressure, heart rate, history of angina, stroke, hypertension, diabetes, 
myocardial infarction or heart failure hospitalization and medical therapy: diuretics, 
angiotensin converting enzyme inhibitor, calcium channel blockers, aspirin, vasodilators and 
spironolactone use. 
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Table 1. Baseline Characteristics of the overall study population stratified by treatment 
and WRF 
 Candesartan  Placebo  
Variables WRF No WRF P-value WRF No WRF P-value 
N 193 (16) 998 (84)  89 (7) 1125 (93)  
Age (years) 64 ± 11 65 ± 12 0.67 67 ± 10 65 ± 12 0.10 
Male gender (%) 134 (69) 669 (67) 0.52 61 (69) 752 (67) 0.74 
Heart rate (bpm) 73 ± 12 72 ± 12 0.37 74 ± 13 71 ± 12 0.07 
SBP (mmHg) 127 ± 19 128 ± 19 0.61 131 ± 21 129 ± 18 0.13 
DBP (mmHg) 73 ± 11 74 ± 11 0.15 73 ± 11 74 ± 11 0.57 
BMI (kg/m2) 30 ± 7 30 ± 6 0.91 30 ± 5 29 ± 6 0.41 
LVEF (%) 37 ± 16 39 ± 16 0.15 39 ± 17 39 ± 16 0.89 
   LVEF e  45% (%) 32 35 0.45 39 35 0.38 
Ischemic HF (%) 62 59 0.37 61 58 0.56 
   Medical History (%)       
   Hypertension 65 66 0.71 70 67 0.55 
   Diabetes 37 37 0.95 45 36 0.10 
   Atrial Fibrillation 31 28 0.34 24 30 0.21 
   Stroke 10 10 0.97 12 11 0.74 
   Myocardial Infarction 57 54 0.46 56 52 0.43 
Laboratory       
   Hemoglobin (g/dL) 13.3 ± 1.6 13.6 ± 1.6 0.01 13.5 ± 1.5 13.7 ± 1.5 0.32 
   Creatinine (µmol/L) 97 (80-124) 89 (80-115) 0.019 97 (71-115) 97 (80–115) 0.10 
eGFR (mL/min/1.73m2)       
   sMDRD 69 ± 29 72 ± 26 0.15 77 ± 29 72 ± 27 0.09 
  CKD-EPI 64 ± 22 68 ± 23 0.04 70 ± 21 67 ± 23 0.28 
Medical Therapy (%)       
   ACE-inhibitors 47 46 0.75 57 44 0.01 
   MRA 17 15 0.36 13 15 0.69 
   Diuretics 94 85 0.002 92 85 0.06 
      Loop Diuretic 
      Other 
88 
6 
79 
6 
 
88 
4 
80 
5 
 
   Beta-blockers 51 58 0.05 55 55 0.95 
   NSAIDs 8 7 0.67 9 9 0.91 
   Digoxin 54 54 0.92 50 53 0.49 
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Abbreviations: ACE: angiotensin converting enzyme, BMI: body mass index, DBP; diastolic 
blood pressure, eGFR: estimated glomerular filtration rate, HF: heart failure, LVEF: left 
ventricular ejection fraction MRA: mineralocorticoid receptor antagonist, NSAIDs: non-
steroidal anti-inflammatory drugs, SBP: systolic blood pressure, WRF: worsening renal 
function. 
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Table 2. Baseline Characteristics of the overall study population stratified by 
HFREF/HFPEF and WRF 
 HFREF  HFPEF  
Variables WRF No WRF P-value WRF No WRF P-value 
N 185 (12) 1384 (88)  97 (12) 739 (88)  
Age (years) 64 ± 11 65 ± 12 0.77 67 ± 10 66 ± 11 0.19 
Male gender (%) 140 (76) 1008 (73) 0.41 55 (57) 413 (56) 0.88 
Heart rate (bpm) 74 ± 13 72 ± 12 0.013 70 ± 11 71 ± 11 0.67 
SBP (mmHg) 123 ± 20 126 ± 18 0.20 137 ± 18 133 ± 17 0.022 
DBP (mmHg) 72 ± 11 74 ± 11 0.047 75 ± 10 75 ± 11 0.99 
BMI (kg/m2) 29 ± 6 29 ± 6 0.45 31 ± 7 31 ± 7 0.94 
LVEF (%) 27 ± 8 29 ± 9 0.006 57 ± 8 57 ± 8 0.60 
Ischemic HF (%) 62 64 0.71 61 48 0.016 
Medical History (%)       
   Hypertension 61 61 0.98 76 76 0.97 
   Diabetes 38 35 0.50 42 38 0.45 
   Atrial Fibrillation 28 28 0.97 31 31 0.97 
   Stroke 12 11 0.64 8 10 0.53 
   Myocardial Infarction 59 59 0.999 51 40 0.046 
Laboratory       
   Hemoglobin (g/dL) 13.5 ± 1.5 13.7 ± 1.6 0.075 13.0 ± 1.7 13.5 ± 1.6 0.008 
   Creatinine (µmol/L) 97 (80-124) 97 (80-115) 0.083 89 (71-115) 89 (71-115) 0.53 
eGFR (mL/min/1.73m2)       
   sMDRD 71 ± 30 72 ± 26 0.58 74 ± 25 73 ± 27 0.64 
   CKD-EPI 65 ± 23 68 ± 23 0.17 68 ± 24 68 ± 20 0.94 
Medical Therapy (%)       
   Candesartan 71 47 < 0.001 64 47 0.002 
   ACE-inhibitors 64 56 0.034 25 24 0.93 
   MRA 17 18 0.87 13 9 0.19 
  Diuretics 96 87 0.001 89 82 0.10 
     Loop Diuretics 
     Other 
92 
4 
82 
5 
 
80 
9 
75 
7 
 
   Beta-blockers 50 57 0.11 56 57 0.75 
   NSAIDs 9 7 0.34 7 10 0.45 
   Digoxin 62 65 0.53 34 32 0.76 
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Abbreviations: ACE: angiotensin converting enzyme, BMI: body mass index, DBP; diastolic 
blood pressure, eGFR: estimated glomerular filtration rate, HF: heart failure, HFREF: heart 
failure with reduced ejection fraction, HFPEF: heart failure with preserved ejection fraction, 
LVEF: left ventricular ejection fraction MRA: mineralocorticoid receptor antagonist, 
NSAIDs: non-steroidal anti-inflammatory drugs, SBP: systolic blood pressure, WRF: 
worsening renal function. 
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Table 3. Prevalence of WRF in different CHARM study arms and relationship to treatment allocation 
 
Overall CHARM 
(N=2405) 
HFREF 
(N=1569) 
HFPEF 
(N=836) 
WRF Definition 
Candesartan 
(N=1191) 
Placebo 
(N=1214) 
Candesartan 
(N=780) 
Placebo 
(N=789) 
Candesartan 
(N=411) 
Placebo 
(N=425) 
e  26.5 µmol/L ánd e  25% increase in 
creatinine at 6 weeks 
193 (16) 89 (7) 131 (17) 54 (7) 62 (15) 35 (8) 
   OR for WRF with Candesartan 2.44 (1.88 - 3.19), P < 0.001 2.75 (1.97 – 3.84), P < 0.001 1.98 (1.28 – 3.07), P = 0.002 
e  26.5 µmol/L increase in creatinine 
at 6 weeks 
235 (20) 113 (9) 162 (21) 69 (9) 73 (18) 44 (10) 
   OR for WRF with Candesartan 2.39 (1.88 – 3.05), P < 0.001 2.74 (2.02 – 3.70), P < 0.001 1.87 (1.25 – 2.79), P = 0.002 
e  20% decrease in eGFR at 6 weeks 284 (24) 160 (13) 186 (24) 95 (12) 98 (24) 65 (15) 
   OR for WRF with Candesartan 2.06 (1.67 – 2.55), P < 0.001 2.29 (1.75 -3.00), P < 0.001 1.73 (1.22 – 2.46), P = 0.002 
e  30% decrease in eGFR at 6 weeks 124 (10) 69 (6) 82 (11) 38 (5) 42 (10) 31 (7) 
   OR for WRF with Candesartan 1.92 (1.42 – 2.62), P < 0.001 2.32 (1.56 -3.46), P < 0.001 1.45 (0.89 – 2.35), P = 0.136 
 
Abbreviations: OR: odds ratio, WRF: worsening renal function
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Table 4. Univariate and multivariable analysis of WRF in CHARM stratified for patients with HFREF and HFPEF 
 CV death / HF Hosp AC death CV death HF Hosp AC death / HF Hosp Combined Endpoint* 
 HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
CHARM Overall             
WRF (univariate) 1.41 (1.17-1.72) < 0.001 1.19 (0.92-1.53) 0.18 1.39 (1.05-1.83) 0.016 1.55 (1.25-1.93) < 0.001 1.37 (1.14-1.65) 0.001 1.31 (1.09-1.57) 0.004 
Multivariable             
   WRF (entire population) 1.26 (1.03–1.54) 0.022 1.03 (0.79-1.33) 0.85 1.21 (0.91-1.59) 0.19 1.37 (1.09-1.71) 0.007 1.22 (1.01-1.48) 0.040 1.19 (0.99-1.44) 0.063 
      WRF with Candesartan 1.31 (1.02-1.68) 0.037 1.03 (0.75-1.44) 0.82 1.19 (0.83-1.72) 0.35 1.41 (1.06-1.88) 0.019 1.27 (1.01-1.63) 0.045 1.25 (0.99–1.58) 0.061 
      WRF with Placebo 1.24 (0.89-1.74) 0.19 1.09 (0.71-1.67) 0.69 1.31 (0.84-2.04) 0.24 1.38 (0.95-2.00) 0.087 1.20 (0.86-1.66) 0.29 1.13 (0.82-1.55) 0.47 
   P-value Interaction  0.95  0.76  0.58  0.89  0.93  0.91 
HFREF             
WRF (univariate) 1.46 (1.17-1.83) 0.001 1.06 (0.79-1.44) 0.68 1.26 (0.92-1.72) 0.15 1.69 (1.32-2.17) < 0.001 1.38 (1.11-1.72) 0.004 1.31 (1.05-1.62) 0.015 
Multivariable             
   WRF (entire population) 1.32 (1.05-1.67) 0.019 0.90 (0.66-1.23) 0.51 1.08 (0.78-1.49) 0.65 1.57 (1.21-2.03) 0.001 1.24 (0.99-1.56) 0.062 1.20 (0.96-1.50) 0.11 
      WRF with Candesartan 1.29 (0.96-1.73) 0.096 0.80 (0.54-1.20) 0.29 0.99 (0.65-1.52) 0.97 1.48 (1.01-2.08) 0.023 1.21 (0.91-1.61) 0.19 1.21 (0.92-1.60) 0.17 
      WRF with Placebo 1.51 (1.02-2.22) 0.039 1.13 (0.69-1.86) 0.63 1.23 (0.72-2.09) 0.45 1.87 (1.23-2.83) 0.003 1.40 (0.95-2.06) 0.085 1.24 (0.84-1.81) 0.29 
   P-value Interaction  0.51  0.40  0.32  0.33  0.56  0.29 
HFPEF             
WRF (univariate) 1.30 (0.89–1.90) 0.17 1.60 (1.00-2.56) 0.049 1.93 (1.12-3.33) 0.018 1.24 (0.81-1.91) 0.32 1.36 (0.96-1.94) 0.087 1.31(0.94-1.84) 0.11 
Multivariable             
   WRF (entire population) 1.09 (0.72-1.65) 0.67 1.33 (0.80–2.19) 0.27 1.60 (0.89-2.90) 0.12 0.98 (0.61-1.57) 0.92 1.12 (0.77-1.65) 0.55 1.14 (0.80-1.63) 0.47 
      WRF with Candesartan 1.11 (0.65–1.90) 0.71 1.69 (0.87-3.28) 0.12 2.54 (1.10-5.86) 0.028 0.95 (0.52-1.75) 0.88 1.13 (0.69-1.86) 0.62 1.11 (0.70-1.78) 0.65 
      WRF with Placebo 0.84 (0.42-1.69) 0.63 0.77 (0.31-1.89) 0.57 0.72 (0.25-2.03) 0.53 0.82 (0.35-1.89) 0.64 0.89 (0.46-1.72) 0.73 0.99 (0.55-1.79) 0.98 
   P-value Interaction  0.50  0.20  0.10  0.72  0.48  0.17 
P-value Overall Interaction# 0.98  0.43  0.69  0.81  0.43  0.85 
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* Cardiovascular death, admission to hospital for HF, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularisation. # WRF x 
Treatment x HFREF/HFPEF. Abbreviations: AC: All-cause, CHARM: candesartan in heart failure assessment of reduction in mortality and 
morbidity study, CI: Confidence Interval, CV: cardiovascular, HF: heart failure, HFREF: heart failure with reduced ejection fraction, HFPEF: 
heart failure with preserved ejection fraction, HR: Hazard ratio, WRF: worsening renal function. Multivariable analyses included the following 
covariates: age, gender, race, NYHA functional class, smoking status, LVEF, systolic and diastolic blood pressure, heart rate, history of angina, 
stroke, hypertension, diabetes, myocardial infarction and HF hospitalization, as well as certain medical therapies: diuretic, ACE-inhibitor, 
spironolactone, calcium channel blocker, other vasodilators and aspirin.
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Figure 1. Candesartan treatment, Worsening Renal Function and CV death or HF 
Hospitalization 
A) Patients with HFREF 
 
B) Patients with HFPEF 
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Figure 2: Change in eGFR stratified for treatment 
A) Entire CHARM population 
 
 
B) Patients with HFREF 
 
 
C) Patients with HFPEF 
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